Boceprevir (INN, trade name Victrelis) is a protease inhibitor used as a treatment for hepatitis C genotype 1. It binds to HCV nonstructural 3 NS3 (HCV) active site. It was being developed by Schering-Plough, but is now being developed by Merck since Schering was acquired in 2009. It was approved by the FDA on May 13, 2011.
Venkatraman, Srikanth; Bogen, Stephane L.; Arasappan, Ashok; Bennett, Frank; Chen, Kevin; Jao, Edwin; Liu, Yi-Tsung; Lovey, Raymond; Hendrata, Siska; Huang, Yuhua; Pan, Weidong; Parekh, Tejal; Pinto, Patrick; Popov, Veljko; Pike, Russel; Ruan, Sumei; Santhanam, Bama; Vibulbhan, Bancha; Wu, Wanli; Yang, Weiying; Kong, Jianshe; Liang, Xiang; Wong, Jesse; Liu, Rong; Butkiewicz, Nancy; Chase, Robert; Hart, Andrea; Agrawal, Sony; Ingravallo, Paul; Pichardo, John; Kong, Rong; Baroudy, Bahige; Malcolm, Bruce; Guo, Zhuyan; Prongay, Andrew; Madison, Vincent; Broske, Lisa; Cui, Xiaoming; Cheng, Kuo-Chi; Hsieh, Tony Y.; Brisson, Jean-Marc; Prelusky, Danial; Korfmacher, Walter; White, Ronald; Bogdanowich-Knipp, Susan; Pavlovsky, Anastasia; Bradley, Prudence; Saksena, Anil K.; Ganguly, Ashit; Piwinski, John; Girijavallabhan, Viyyoor; Njoroge, F. George. Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection. Journal of Medicinal Chemistry. Volume 49. Issue 20. Pages 6074-6086. Journal. (2006).
Bhalerao, Dinesh S.; Arkala, Anil Kumar Reddy; Madhavi, Y. V.; Nagaraju, M.; Gade, Srinivas Reddy; Kumar, U. K. Syam; Bandichhor, Rakeshwar; Dahanukar, Vilas H. Synthesis and Process Optimization of Boceprevir: A Protease Inhibitor Drug. Organic Process Research & Development. Volume 19. Issue 11. Pages 1559-1567. Journal; Online Computer File. (2015).
Rajan, Srinivasan Thirumalai; Eswaraiah, Sajja; Reddy, Ghojala Venkat. Process for the preparation of 3-amino-4-cyclobutyl-2-hydroxybutanamide as intermediate in the synthesis of (1R,2S,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-di methy lethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-carboxamide. Assignee MSN Laboratories Limited, India. IN 2012CH04346. (2016).
Wu, George G.; Itoh, Tetsuji; McLaughlin, Mark; Liu, Zhijian; Qian, Gang. Process for the preparation of 3-amino-4-cyclobutyl-2-hydroxybutanamide derivatives. Assignee Merck Sharp & Dohme Corp., USA. WO 2013066734. (2013).
Delaney, William E.; Mo, Hongmei; Zhong, Weidong. Pharmaceutical compositions comprising combination of imidazopyridine and azabicyclohexane-carboxamide derivatives useful for treating hepatitis C. Assignee Gilead Sciences, Inc., USA. US 20100324060. (2010).
